CA2003794C
(en)
*
|
1988-12-01 |
2000-02-08 |
Hanne R. Johansen |
Expression of hiv proteins in drosophila cells
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
US5786464C1
(en)
*
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
US6592877B1
(en)
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6290969B1
(en)
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6534312B1
(en)
|
1996-02-22 |
2003-03-18 |
Merck & Co., Inc. |
Vaccines comprising synthetic genes
|
EP1997900A3
(en)
|
1996-04-05 |
2010-10-06 |
Novartis Vaccines and Diagnostics, Inc. |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
EP0935659A1
(en)
|
1996-09-17 |
1999-08-18 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6114148C1
(en)
*
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
WO1998034640A2
(en)
*
|
1997-02-07 |
1998-08-13 |
Merck & Co., Inc. |
Synthetic hiv gag genes
|
US6696291B2
(en)
|
1997-02-07 |
2004-02-24 |
Merck & Co., Inc. |
Synthetic HIV gag genes
|
US6261562B1
(en)
|
1997-02-25 |
2001-07-17 |
Corixa Corporation |
Compounds for immunotherapy of prostate cancer and methods for their use
|
US7087713B2
(en)
|
2000-02-25 |
2006-08-08 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
AU8692598A
(en)
|
1997-08-04 |
1999-02-22 |
Calydon, Inc. |
A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
|
JP4472866B2
(en)
|
1997-11-06 |
2010-06-02 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Neisseria antigen
|
US6914131B1
(en)
|
1998-10-09 |
2005-07-05 |
Chiron S.R.L. |
Neisserial antigens
|
JP2002507387A
(en)
|
1997-12-24 |
2002-03-12 |
コリクサ コーポレイション |
Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
|
DE69941567D1
(en)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
ANTIGENE FROM NEISSERIA MENINGITIDIS
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
EP1792988A3
(en)
|
1998-03-18 |
2007-08-22 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
CN100379757C
(en)
|
1998-05-01 |
2008-04-09 |
希龙公司 |
Neisseria meningitidis antigens and compositions
|
IL141044A0
(en)
|
1998-08-07 |
2002-02-10 |
Univ Washington |
Innunological herpes simplex virus antigens and methods for use thereof
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
AU1316200A
(en)
|
1998-10-15 |
2000-05-01 |
Chiron Corporation |
Metastatic breast and colon cancer regulated genes
|
CA2354232A1
(en)
|
1998-12-08 |
2000-06-15 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
ES2310055T3
(en)
|
1998-12-16 |
2008-12-16 |
Novartis Vaccines & Diagnostic |
CYCLIN DEPENDENT HUMAN KINASE (HPNQALRE).
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
CA2360347C
(en)
|
1998-12-31 |
2013-05-07 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
KR20020007354A
(en)
|
1999-04-02 |
2002-01-26 |
길리스 스티브 |
Compounds and methods for therapy and diagnosis of lung cancer
|
US8143386B2
(en)
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
JP2003518363A
(en)
|
1999-04-30 |
2003-06-10 |
カイロン エセ.ピー.アー. |
Conserved Neisseria antigen
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
EP1229931A4
(en)
|
1999-10-07 |
2003-05-28 |
Corixa Corp |
Fusion proteins of mycobacterium tuberculosis
|
PT2275551E
(en)
|
1999-10-29 |
2015-06-29 |
Novartis Vaccines & Diagnostic |
Neisserial antigenic peptides
|
ES2335386T3
(en)
|
1999-11-18 |
2010-03-26 |
Novartis Vaccines And Diagnostics, Inc. |
GEN FGF-21 HUMAN AND GENE EXPRESSION PRODUCTS.
|
AU784518B2
(en)
|
2000-01-17 |
2006-04-27 |
Glaxosmithkline Biologicals S.A. |
Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
|
EP1854476A3
(en)
|
2000-02-09 |
2008-05-07 |
Bas Medical, Inc. |
Use of relaxin to treat diseases related to vasoconstriction
|
SI1265915T1
(en)
|
2000-02-23 |
2011-02-28 |
Glaxosmithkline Biolog Sa |
Novel compounds
|
NZ521531A
(en)
|
2000-02-28 |
2005-12-23 |
Chiron S |
Heterologous expression of neisserial proteins
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
EP2075255A1
(en)
|
2000-03-08 |
2009-07-01 |
Novartis Vaccines and Diagnostics, Inc. |
Human FGF-23 gene and gene expression products
|
EP2192128A3
(en)
|
2000-04-21 |
2010-09-22 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
WO2001090129A2
(en)
|
2000-05-19 |
2001-11-29 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
|
EP1950297A2
(en)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
WO2001096523A2
(en)
|
2000-06-15 |
2001-12-20 |
Chiron Corporation |
Polynucleotides related to colon cancer
|
DK2133100T3
(en)
|
2000-06-20 |
2012-01-23 |
Corixa Corp |
MTB32A Antigen of Mycobacterium tuberculosis with Inactivated Active Site and Fusion Proteins
|
ATE396265T1
(en)
|
2000-06-28 |
2008-06-15 |
Corixa Corp |
COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER
|
US20020165192A1
(en)
|
2000-09-19 |
2002-11-07 |
Kerr William G. |
Control of NK cell function and survival by modulation of ship activity
|
US7691821B2
(en)
|
2001-09-19 |
2010-04-06 |
University Of South Florida |
Inhibition of SHIP to enhance stem cell harvest and transplantation
|
MXPA03003690A
(en)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Nucleic acids and proteins from streptococcus groups a b.
|
ES2397627T3
(en)
|
2000-12-07 |
2013-03-08 |
Novartis Vaccines And Diagnostics, Inc. |
Endogenous retroviruses regulated by an increase in prostate cancer
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
AU2002305151A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
CA2452119C
(en)
|
2001-07-05 |
2013-10-15 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
RU2316591C2
(en)
|
2001-11-09 |
2008-02-10 |
Джорджтаун Юниверсити |
New isoforms of vascular endothelial cell growth inhibitor
|
ES2386386T3
(en)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Immunization against Chlamydia trachomatis
|
EP2224012B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
CA2472282A1
(en)
|
2002-01-08 |
2003-07-17 |
Chiron Corporation |
Gene products differentially expressed in cancerous breast cells and their methods of use
|
US7026465B2
(en)
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
JP2005532789A
(en)
|
2002-03-15 |
2005-11-04 |
ワイス・ホールデイングス・コーポレーシヨン |
P4 protein variant of non-typeable Haemophilus influenzae with reduced enzymatic activity
|
AU2003218350A1
(en)
|
2002-03-21 |
2003-10-08 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US20030206916A1
(en)
|
2002-05-03 |
2003-11-06 |
Rush-Presbyterian-St. Luke's Medical Center |
Immunogenic peptides
|
CA2489292A1
(en)
|
2002-06-13 |
2003-12-24 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
DE60324678D1
(en)
|
2002-07-18 |
2008-12-24 |
Univ Washington |
N T-LYMPHOCYTES AND IDENTIFIED HSV ANTIGENES THEREWITH
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
EP2270048B1
(en)
|
2002-12-24 |
2015-11-11 |
Rinat Neuroscience Corp. |
Anti-NGF antibodies and methods using same
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
PL220536B1
(en)
|
2003-01-06 |
2015-11-30 |
Corixa Corp |
Certain amionicalcylivglucosaminiumphosphate compounds and their application
|
WO2004074321A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US7767387B2
(en)
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US20040170982A1
(en)
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
PL379983A1
(en)
|
2003-02-19 |
2006-11-27 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP2353389B1
(en)
|
2003-04-21 |
2015-11-04 |
Epeius Biotechnologies Corporation |
Compositions for treating disorders
|
US20070178066A1
(en)
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
US7812116B2
(en)
|
2003-07-03 |
2010-10-12 |
Rush University Medical Center |
Immunogenic peptides
|
US7807646B1
(en)
|
2003-11-20 |
2010-10-05 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
US7763592B1
(en)
|
2003-11-20 |
2010-07-27 |
University Of South Florida |
SHIP-deficiency to increase megakaryocyte progenitor production
|
KR20070001932A
(en)
|
2003-12-23 |
2007-01-04 |
리나트 뉴로사이언스 코퍼레이션 |
Agonist anti-trkc antibodies and methods using same
|
CA2561696C
(en)
|
2004-03-29 |
2013-09-03 |
Galpharma Co., Ltd. |
Novel modified galectin 9 proteins and use thereof
|
KR101637908B1
(en)
|
2004-04-07 |
2016-07-11 |
리나트 뉴로사이언스 코프. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
DE602005023629D1
(en)
|
2004-07-14 |
2010-10-28 |
Univ California |
BIOMARKER FOR THE EARLY DETECTION OF OVARIAL CARCINOMA
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
EP1781704A2
(en)
|
2004-07-30 |
2007-05-09 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
AU2005272920B2
(en)
|
2004-08-10 |
2011-05-12 |
Institute For Multiple Myeloma And Bone Cancer Research |
Methods of regulating differentiation and treating of multiple myeloma
|
US20080085289A1
(en)
|
2004-09-22 |
2008-04-10 |
Cindy Castado |
Immunogenic Composition
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
EP1701165A1
(en)
|
2005-03-07 |
2006-09-13 |
Johannes Dr. Coy |
Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
|
EA014527B1
(en)
|
2005-03-31 |
2010-12-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Vaccines against chlamydial infection
|
JP2008535494A
(en)
|
2005-04-07 |
2008-09-04 |
サグレシュ ディスカバリー, インコーポレイテッド |
Cancer-related gene (PRLR)
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
BRPI0611347A2
(en)
|
2005-04-29 |
2010-08-31 |
Glaxosmithline Biolog S A |
pharmaceutical composition, uses a mtb72f fusion protein or an immunogenic fragment thereof, and a nucleic acid
|
MY148086A
(en)
|
2005-04-29 |
2013-02-28 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and methods using same
|
BRPI0613770A2
(en)
|
2005-07-22 |
2009-05-19 |
Y S Therapeutics Co Ltd |
anti-cd26 antibodies and methods of use of these
|
PL2380592T3
(en)
|
2005-11-14 |
2018-07-31 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibody directed against calcitonin gene-related peptide
|
AU2007239095B2
(en)
|
2006-01-09 |
2012-05-03 |
The Regents Of The University Of California |
Immunostimulatory combinations for vaccine adjuvants
|
EP1981905B1
(en)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia vaccine
|
CA2637707A1
(en)
|
2006-02-02 |
2007-08-09 |
Rinat Neuroscience Corporation |
Methods for treating obesity by administering a trkb antagonist
|
WO2007117657A2
(en)
|
2006-04-07 |
2007-10-18 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
JP5313886B2
(en)
|
2006-06-07 |
2013-10-09 |
バイオアライアンス セー.フェー. |
Antibodies that recognize carbohydrate-containing epitopes of CD-43 and CEA expressed in cancer cells and methods of using the same
|
PT2054431E
(en)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Conformers of bacterial adhesins
|
JP2010500399A
(en)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
Immunogen from Urinary Pathogenic Escherichia coli
|
US8673859B2
(en)
|
2007-03-20 |
2014-03-18 |
New York University |
GM-CSF cosmeceutical compositions and methods of use thereof
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP3587450A1
(en)
|
2007-12-17 |
2020-01-01 |
Pfizer Limited |
Treatment of interstitial cystitis with ngf inhibitors
|
NZ585959A
(en)
|
2007-12-18 |
2012-09-28 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
AU2009234389B2
(en)
|
2008-04-10 |
2014-08-21 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR mutations in cancer
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
TWI516501B
(en)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9 antagonists
|
AU2009298879A1
(en)
|
2008-09-23 |
2010-04-08 |
President And Fellows Of Harvard College |
SIRT4 and uses thereof
|
US9181315B2
(en)
|
2009-01-08 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
EP2403526B1
(en)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia antigens
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
CA3154626A1
(en)
|
2009-04-14 |
2010-10-21 |
Glaxosmithkline Biologicals S.A. |
Compositions for immunising against staphylococcus aureus
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
JP2012532626A
(en)
|
2009-07-16 |
2012-12-20 |
ノバルティス アーゲー |
Detoxified Escherichia coli immunogen
|
US8563261B2
(en)
|
2009-09-28 |
2013-10-22 |
The Trustees Of The University Of Pennsylvania |
Method of diagnosing and treating interstitial cystitis
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
US20130040853A1
(en)
|
2010-01-21 |
2013-02-14 |
Dana-Farber Cancer Institute Inc. |
Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation
|
PL2528621T3
(en)
|
2010-01-27 |
2017-07-31 |
Glaxosmithkline Biologicals S.A. |
Modified tuberculosis antigens
|
US8298535B2
(en)
|
2010-02-24 |
2012-10-30 |
Rinat Neuroscience Corp. |
Anti-IL-7 receptor antibodies
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
SG10201507722QA
(en)
|
2010-03-11 |
2015-10-29 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
US9539427B2
(en)
|
2010-11-08 |
2017-01-10 |
The Johns Hopkins University |
Methods for improving heart function
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2663868A2
(en)
|
2010-12-01 |
2013-11-20 |
The University of North Carolina at Chapel Hill |
Methods and compositions for targeting sites of neovascular growth
|
US9267112B2
(en)
|
2011-05-10 |
2016-02-23 |
The Regents Of The University Of California |
Adenovirus isolated from Titi Monkeys
|
US10221218B2
(en)
|
2011-05-10 |
2019-03-05 |
The Regents Of The University Of California |
Adenovirus isolated from titi monkeys
|
MX2013013627A
(en)
|
2011-06-21 |
2014-04-25 |
Oncofactor Corp |
Compositions and methods for the therapy and diagnosis of cancer.
|
US20130071375A1
(en)
|
2011-08-22 |
2013-03-21 |
Saint Louis University |
Compositions and methods for treating inflammation
|
WO2013028527A1
(en)
|
2011-08-23 |
2013-02-28 |
Indiana University Research And Technology Corporation |
Compositions and methods for treating cancer
|
AU2012301955A1
(en)
|
2011-08-29 |
2014-03-06 |
The Regents Of The University Of California |
Use of HDL-related molecules to treat and prevent proinflammatory conditions
|
US8969519B2
(en)
|
2011-09-13 |
2015-03-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
JP5936702B2
(en)
|
2011-11-11 |
2016-06-22 |
ライナット ニューロサイエンス コーポレイション |
Antibodies specific for TROP-2 and uses thereof
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
US9249224B2
(en)
|
2011-12-22 |
2016-02-02 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
WO2014072876A1
(en)
|
2012-11-09 |
2014-05-15 |
Pfizer Inc. |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
WO2014153258A2
(en)
|
2013-03-14 |
2014-09-25 |
Epeius Biotechnologies Corporation |
Improved thymidine kinase gene
|
CN105051068A
(en)
|
2013-03-15 |
2015-11-11 |
戴埃克斯有限公司 |
Anti-plasma kallikrein antibodies
|
US9428537B2
(en)
|
2013-03-15 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
tRNA derived small RNAs (tsRNAs) involved in cell viability
|
CN105229023B
(en)
|
2013-03-15 |
2019-08-16 |
加利福尼亚大学董事会 |
Peptide MOTS3 from mitochondria adjusts metabolism and cell survival
|
CN105392882A
(en)
|
2013-04-19 |
2016-03-09 |
加利福尼亚大学董事会 |
Lone star virus
|
WO2014181229A2
(en)
|
2013-05-07 |
2014-11-13 |
Rinat Neuroscience Corp. |
Anti-glucagon receptor antibodies and methods of use thereof
|
US10231993B2
(en)
|
2013-06-27 |
2019-03-19 |
University Of Washington Through Its Center For Commercialization |
Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
|
EP3695841A3
(en)
|
2013-07-01 |
2020-11-04 |
The Research Foundation for the State University of New York |
Ship inhibition to combat obesity
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
KR101809072B1
(en)
|
2013-08-02 |
2017-12-14 |
화이자 인코포레이티드 |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
TWI736515B
(en)
|
2013-11-13 |
2021-08-21 |
美商輝瑞大藥廠 |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
LT3119431T
(en)
|
2014-03-21 |
2024-03-12 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
EP3134546A4
(en)
|
2014-04-24 |
2017-12-06 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
US10308697B2
(en)
|
2014-04-30 |
2019-06-04 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
US10329556B2
(en)
|
2014-05-13 |
2019-06-25 |
Bioatla, Llc |
Conditionally active biological proteins
|
WO2015200070A1
(en)
|
2014-06-17 |
2015-12-30 |
The Research Foundation For The State University Of New York |
Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
KR20230172625A
(en)
|
2014-08-28 |
2023-12-22 |
바이오아트라, 인코퍼레이티드 |
Conditionally active chimeric antigen receptors for modified t-cells
|
EP3189152A4
(en)
|
2014-09-03 |
2018-04-04 |
BioAtla LLC |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
AU2015315199B2
(en)
|
2014-09-09 |
2020-02-27 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
WO2016057367A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
JP6941561B2
(en)
|
2014-10-09 |
2021-09-29 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Multiple variable IL-2 dose regimens for treating immune disorders
|
TWI595006B
(en)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
Anti-pd-1 antibodies and methods of use thereof
|
AU2016229238B2
(en)
|
2015-03-06 |
2022-06-02 |
Dana-Farber Cancer Institute, Inc. |
PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
|
US20180071380A1
(en)
|
2015-03-20 |
2018-03-15 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
AU2016248946B2
(en)
|
2015-04-13 |
2022-03-10 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
WO2017015334A1
(en)
|
2015-07-21 |
2017-01-26 |
Saint Louis University |
Compositions and methods for diagnosing and treating endometriosis-related infertility
|
CN108137705B
(en)
|
2015-07-21 |
2022-11-08 |
武田药品工业株式会社 |
Monoclonal antibody inhibitor of factor XIIA
|
CA3025896A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
CN107922506B
(en)
|
2015-08-19 |
2021-11-09 |
辉瑞公司 |
Tissue factor pathway inhibitor antibodies and uses thereof
|
SI3350220T1
(en)
|
2015-09-15 |
2021-12-31 |
Scholar Rock, Inc. |
Anti-pro/latent-myostatin antibodies and uses thereof
|
US10548970B2
(en)
|
2015-10-05 |
2020-02-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rotavirus G9P[6] strain and use as a vaccine
|
ES2962651T3
(en)
|
2015-10-16 |
2024-03-20 |
Univ Columbia |
Compositions and methods for the inhibition of lineage-specific antigens
|
EP3362074B1
(en)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
CA2946113A1
(en)
|
2015-10-23 |
2017-04-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
WO2017075329A2
(en)
|
2015-10-29 |
2017-05-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
CN106699889A
(en)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
PD-1 resisting antibody and treatment application thereof
|
RU2744860C2
(en)
|
2015-12-30 |
2021-03-16 |
Кодиак Сайенсиз Инк. |
Antibodies and their conjugates
|
CN109219618B
(en)
|
2016-01-21 |
2022-08-09 |
辉瑞大药厂 |
Monospecific and bispecific antibodies against epidermal growth factor receptor variants III and CD3 and uses thereof
|
AU2017238054B2
(en)
|
2016-03-21 |
2023-10-19 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
US20180030478A1
(en)
|
2016-07-01 |
2018-02-01 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
WO2018057618A1
(en)
|
2016-09-20 |
2018-03-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
WO2018080573A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
US20190345501A1
(en)
|
2017-02-07 |
2019-11-14 |
Massachusetts Institute Of Technology |
Methods and compositions for rna-guided genetic circuits
|
EP3589657A1
(en)
|
2017-03-03 |
2020-01-08 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
JP7177076B2
(en)
|
2017-03-16 |
2022-11-22 |
ファイザー・インク |
tyrosine prototrophy
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
MX2019014465A
(en)
|
2017-06-02 |
2020-01-23 |
Pfizer |
Antibodies specific for flt3 and their uses.
|
EP3639170B1
(en)
|
2017-06-13 |
2021-03-24 |
BostonGene Corporation |
Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
|
CN110997002A
(en)
|
2017-07-13 |
2020-04-10 |
麻省理工学院 |
Targeting HDAC2-SP3 complexes to enhance synaptic function
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
Anti-nucleolin antibody
|
CN113896797B
(en)
|
2017-08-01 |
2023-05-09 |
Ab工作室有限公司 |
Bispecific antibodies and uses thereof
|
US11970707B2
(en)
|
2017-09-18 |
2024-04-30 |
Children's Hospital Medical Center |
Strong insulator and uses thereof in gene delivery
|
KR102543719B1
(en)
|
2017-09-21 |
2023-06-16 |
유큐(베이징) 바이오파마 코., 엘티디 |
Anti-CTLA4 Antibodies and Uses Thereof
|
AU2018344859A1
(en)
|
2017-10-04 |
2020-04-30 |
Hesperix SA |
Articles and methods directed to personalized therapy of cancer
|
JP7479281B2
(en)
|
2017-11-24 |
2024-05-08 |
ユーキュア・(ベイジン)・バイオファーマ・カンパニー・リミテッド |
Anti-OX40 antibody and its uses
|
MX2020008183A
(en)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Antibodies specific for cd70 and their uses.
|
CN112020518A
(en)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
Chimeric antigen receptor targeting CD70
|
EP3755342A4
(en)
|
2018-02-21 |
2021-11-24 |
The University Of Montana |
Diaryl trehalose compounds and uses thereof
|
KR102608723B1
(en)
|
2018-02-23 |
2023-12-01 |
유큐(베이징) 바이오파마 코., 엘티디 |
Anti-PD-1 antibodies and uses thereof
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
CN112203679A
(en)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
IL-6 antibodies and fusion constructs and conjugates thereof
|
US11572381B2
(en)
|
2018-03-02 |
2023-02-07 |
The University Of Montana |
Immunogenic trehalose compounds and uses thereof
|
EP4414034A2
(en)
|
2018-05-23 |
2024-08-14 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
KR102584675B1
(en)
|
2018-05-23 |
2023-10-05 |
화이자 인코포레이티드 |
Antibodies specific for GUCY2c and their uses
|
JP2021529559A
(en)
|
2018-07-03 |
2021-11-04 |
ソティオ,リミティド ライアビリティ カンパニー |
Chimeric receptors in combination with trans-metabolizing molecules that improve glucose imports and their therapeutic use
|
KR20210033029A
(en)
|
2018-07-20 |
2021-03-25 |
유큐(베이징) 바이오파마 코., 엘티디 |
Anti-CD40 antibodies and uses thereof
|
CN113423725A
(en)
|
2018-08-28 |
2021-09-21 |
Vor生物制药股份有限公司 |
Genetically engineered hematopoietic stem cells and uses thereof
|
CA3110006A1
(en)
|
2018-09-12 |
2020-03-19 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-tnfrsf9 antibodies and uses thereof
|
KR20220089688A
(en)
|
2018-11-19 |
2022-06-28 |
바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 |
Anti-PD-1 antibodies and uses thereof
|
CN117099741A
(en)
|
2019-02-18 |
2023-11-24 |
百奥赛图(北京)医药科技股份有限公司 |
Genetically modified non-human animals with humanized immunoglobulin loci
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
BR112021023292A2
(en)
|
2019-05-23 |
2022-02-08 |
The Univ Of Montana |
Compound, formulation, vaccine composition, pharmaceutical composition, and method for modulating an immune response in an individual
|
CA3146077A1
(en)
|
2019-07-03 |
2021-02-18 |
Bostongene Corporation |
Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
|
AU2020363372A1
(en)
|
2019-10-07 |
2022-05-19 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
US20230067811A1
(en)
|
2020-01-24 |
2023-03-02 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
AU2021283564A1
(en)
|
2020-06-02 |
2022-12-08 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animals with common light chain immunoglobulin locus
|
JP2023533793A
(en)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
Therapeutic antibodies and their uses
|
US20230287455A1
(en)
|
2020-07-30 |
2023-09-14 |
Pfizer Inc. |
Cells Having Gene Duplications and Uses Thereof
|
WO2022086852A2
(en)
|
2020-10-19 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
US20240024474A1
(en)
|
2020-11-13 |
2024-01-25 |
David Avigan |
Personalized fusion cell vaccines
|
US20240029829A1
(en)
|
2020-12-04 |
2024-01-25 |
Bostongene Corporation |
Hierarchical machine learning techniques for identifying molecular categories from expression data
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
EP4330969A1
(en)
|
2021-04-29 |
2024-03-06 |
BostonGene Corporation |
Machine learning techniques for estimating tumor cell expression in complex tumor tissue
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
CA3227875A1
(en)
|
2021-08-02 |
2023-02-09 |
Pfizer Inc. |
Improved expression vectors and uses thereof
|
CA3232833A1
(en)
|
2021-09-27 |
2023-03-30 |
Kathleen Mcginness |
Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
|
MX2024005926A
(en)
|
2021-11-16 |
2024-06-04 |
Sotio Biotech Inc |
Treatment of myxoid/round cell liposarcoma patients.
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023147177A1
(en)
|
2022-01-31 |
2023-08-03 |
Bostongene Corporation |
Machine learning techniques for cytometry
|
WO2023148598A1
(en)
|
2022-02-02 |
2023-08-10 |
Pfizer Inc. |
Cysteine prototrophy
|
WO2023158732A1
(en)
|
2022-02-16 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
|
WO2024015561A1
(en)
|
2022-07-15 |
2024-01-18 |
Bostongene Corporation |
Techniques for detecting homologous recombination deficiency (hrd)
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|